David Shook - 03 Jan 2025 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role
Chief Medical Officer, Head of Research & Development
Signature
/s/ Alicia Hager, as Attorney-in-Fact
Issuer symbol
NKTX
Transactions as of
03 Jan 2025
Net transactions value
$0
Form type
4
Filing time
07 Jan 2025, 16:06:04 UTC
Previous filing
23 Aug 2024
Next filing
17 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTX Common Stock Award $0 +59,000 +42% $0.000000 199,593 03 Jan 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTX Stock Option (right to buy) Award $0 +117,500 $0.000000 117,500 03 Jan 2025 Common Stock 117,500 $2.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2026. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2 Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2024.
F3 This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2025.

Remarks:

Chief Medical Officer, Head of Research & Development